These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 38421209)

  • 1. The ATR inhibition by Elimusertib enhances the radiosensitivity of MDA-MB-231 triple negative breast cancer in vitro.
    Guney Eskiler G; Halis H; Hamarat KF; Derlioglu RR; Ugurlu BT; Haciefendi A
    Int J Radiat Biol; 2024; 100(5):715-723. PubMed ID: 38421209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The suppression of ATR/Chk1 pathway by Elimusertib ATR inhibitor in triple negative breast cancer cells.
    Haciefendi A; Guney Eskiler G
    Am J Transl Res; 2023; 15(7):4902-4911. PubMed ID: 37560219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ATR Inhibition Is a Promising Radiosensitizing Strategy for Triple-Negative Breast Cancer.
    Tu X; Kahila MM; Zhou Q; Yu J; Kalari KR; Wang L; Harmsen WS; Yuan J; Boughey JC; Goetz MP; Sarkaria JN; Lou Z; Mutter RW
    Mol Cancer Ther; 2018 Nov; 17(11):2462-2472. PubMed ID: 30166399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regorafenib sensitizes human breast cancer cells to radiation by inhibiting multiple kinases and inducing DNA damage.
    Mehta M; Griffith J; Panneerselvam J; Babu A; Mani J; Herman T; Ramesh R; Munshi A
    Int J Radiat Biol; 2021; 97(8):1109-1120. PubMed ID: 32052681
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of the ATR-DNAPKcs-RB axis drives G1/S-phase transition and sensitizes triple-negative breast cancer (TNBC) to DNA holliday junctions.
    Hu YM; Liu XC; Hu L; Dong ZW; Yao HY; Wang YJ; Zhao WJ; Xiang YK; Liu Y; Wang HB; Yin QK
    Biochem Pharmacol; 2024 Jul; 225():116310. PubMed ID: 38788960
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ovarian and uterine carcinosarcomas are sensitive in vitro and in vivo to elimusertib, a novel ataxia-telangiectasia and Rad3-related (ATR) kinase inhibitor.
    Manavella DD; McNamara B; Harold J; Bellone S; Hartwich TMP; Yang-Hartwich Y; Mutlu L; Zipponi M; Demirkiran C; Verzosa MS; Altwerger G; Ratner E; Huang GS; Clark M; Andikyan V; Azodi M; Schwartz PE; Dottino PR; Choi J; Alexandrov LB; Buza N; Hui P; Santin AD
    Gynecol Oncol; 2023 Feb; 169():98-105. PubMed ID: 36525930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The ATR inhibitor elimusertib exhibits anti-lymphoma activity and synergizes with the PI3K inhibitor copanlisib.
    Sartori G; Tarantelli C; Spriano F; Gaudio E; Cascione L; Mascia M; Barreca M; Arribas AJ; Licenziato L; Golino G; Ferragamo A; Pileri S; Damia G; Zucca E; Stathis A; Politz O; Wengner AM; Bertoni F
    Br J Haematol; 2024 Jan; 204(1):191-205. PubMed ID: 38011941
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Downregulation of TMPRSS4 Enhances Triple-Negative Breast Cancer Cell Radiosensitivity Through Cell Cycle and Cell Apoptosis Process Impairment.
    Assani G; Segbo J; Yu X; Yessoufou A; Xiong Y; Zhou F; Zhou Y
    Asian Pac J Cancer Prev; 2019 Dec; 20(12):3679-3687. PubMed ID: 31870109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors Influencing the Central Nervous System (CNS) Distribution of the Ataxia Telangiectasia Mutated and Rad3-Related Inhibitor Elimusertib (BAY1895344): Implications for the Treatment of CNS Tumors.
    Rathi S; Mladek AC; Oh JH; Dragojevic S; Burgenske DM; Zhang W; Talele S; Zhang W; Bakken KK; Carlson BL; Connors MA; He L; Hu Z; Sarkaria JN; Elmquist WF
    J Pharmacol Exp Ther; 2024 Oct; 391(2):346-360. PubMed ID: 39284626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined Aurora Kinase A and CHK1 Inhibition Enhances Radiosensitivity of Triple-Negative Breast Cancer Through Induction of Apoptosis and Mitotic Catastrophe Associated With Excessive DNA Damage.
    Li C; Liao J; Wang X; Chen FX; Guo X; Chen X
    Int J Radiat Oncol Biol Phys; 2023 Dec; 117(5):1241-1254. PubMed ID: 37393021
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting ataxia telangiectasia-mutated- and Rad3-related kinase (ATR) in PTEN-deficient breast cancers for personalized therapy.
    Al-Subhi N; Ali R; Abdel-Fatah T; Moseley PM; Chan SYT; Green AR; Ellis IO; Rakha EA; Madhusudan S
    Breast Cancer Res Treat; 2018 Jun; 169(2):277-286. PubMed ID: 29396668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined Inhibition of ATR and WEE1 as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer.
    Jin J; Fang H; Yang F; Ji W; Guan N; Sun Z; Shi Y; Zhou G; Guan X
    Neoplasia; 2018 May; 20(5):478-488. PubMed ID: 29605721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic enhancement of apoptosis by coralyne and paclitaxel in combination on MDA-MB-231 a triple-negative breast cancer cell line.
    Kumari S; Mohan MG; Shailender G; Badana AK; Malla RR
    J Cell Biochem; 2019 Oct; 120(10):18104-18116. PubMed ID: 31172606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Triple-Negative Breast Cancer and Emerging Therapeutic Strategies: ATR and CHK1/2 as Promising Targets.
    Sofianidi A; Dumbrava EE; Syrigos KN; Nasrazadani A
    Cancers (Basel); 2024 Mar; 16(6):. PubMed ID: 38539474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nuclear pCHK1 as a potential biomarker of increased sensitivity to ATR inhibition.
    Sundararajan V; Tan TZ; Lim D; Peng Y; Wengner AM; Ngoi NYL; Jeyasekharan AD; Tan DSP
    J Pathol; 2023 Feb; 259(2):194-204. PubMed ID: 36373784
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Depletion of ATR selectively sensitizes ATM-deficient human mammary epithelial cells to ionizing radiation and DNA-damaging agents.
    Cui Y; Palii SS; Innes CL; Paules RS
    Cell Cycle; 2014; 13(22):3541-50. PubMed ID: 25483091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic Targeting of the DNA Damage Response Using an ATR Inhibitor in Biliary Tract Cancer.
    Nam AR; Jin MH; Park JE; Bang JH; Oh DY; Bang YJ
    Cancer Res Treat; 2019 Jul; 51(3):1167-1179. PubMed ID: 30514066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Chk1 inhibitor MK-8776 increases the radiosensitivity of human triple-negative breast cancer by inhibiting autophagy.
    Zhou ZR; Yang ZZ; Wang SJ; Zhang L; Luo JR; Feng Y; Yu XL; Chen XX; Guo XM
    Acta Pharmacol Sin; 2017 Apr; 38(4):513-523. PubMed ID: 28042876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Abrogation of ATR function preferentially augments cisplatin-induced cytotoxicity in PTEN-deficient breast cancer cells.
    Zhao JL; Yang J; Li K; Chen Y; Tang M; Zhu HL; Nie CL; Yuan Z; Zhao XY
    Chem Biol Interact; 2023 Nov; 385():110740. PubMed ID: 37802411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Novel ATR Inhibitor BAY 1895344 Is Efficacious as Monotherapy and Combined with DNA Damage-Inducing or Repair-Compromising Therapies in Preclinical Cancer Models.
    Wengner AM; Siemeister G; Lücking U; Lefranc J; Wortmann L; Lienau P; Bader B; Bömer U; Moosmayer D; Eberspächer U; Golfier S; Schatz CA; Baumgart SJ; Haendler B; Lejeune P; Schlicker A; von Nussbaum F; Brands M; Ziegelbauer K; Mumberg D
    Mol Cancer Ther; 2020 Jan; 19(1):26-38. PubMed ID: 31582533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.